CEO Corner

Navigating Growth In Biotech: A First-Person Insight

Five attributes are essential for emerging biotech companies to thrive and grow in what will be a challenging financing environment for the foreseeable future. These attributes also serve as a proxy for creating long-term, sustainable value.

Delivering The Next Evolution In Immuno-Oncology

To continue the momentum created by new discoveries and treatments for cancer patients, drug developers need a strong and focused corporate culture, employees willing to challenge established norms, and a system for prioritizing development candidates guided by science and patient needs.

Facing The Drug Launch Challenge As A New CEO

Economic instability, geopolitical struggles, market access, pricing, and regulatory differences — among many other issues — can present themselves at any time before, during, or after the launch. What is important is how a CEO manages the steps toward launch success.

Essential Elements Of Becoming A Successful CEO

In this article, I address what it takes to succeed as a CEO by sharing insights and learnings from my own career in the hope that my experiences will offer some valuable guidance to those who aspire to become CEOs.

Making The Jump From Big Pharma To Biotech

When a recruiter presented me with an opportunity to become CEO of a small but rising publicly listed biotech in my native Canada, I had to give it a lot of thought. Although I loved my job, I was a bit itchy to make not just a career move, but a life move.

From Science To CEO: Advice For First-Time Founders

Although it’s still early in my transition from a researcher in a lab to CEO, I think it’s worth sharing the playbook I wish I had when I started out.

My Journey From "Science Guy" To CEO

I am a big believer in refining one's personal brand and even reinventing yourself to create opportunities for personal growth. During my career, some key truths and learnings have emerged that I feel privileged to share, and I hope these will be insightful and helpful.

Driving And Sustaining Innovation In Biopharma Today

We’ve arrived at a critical window for innovation in rare disease that must be treated with the same caliber and urgency that we saw nearly three years ago at the onset of the COVID-19 pandemic.

What I Learned As CEO The First Time Around

Less than 10% of novel compounds that enter Phase 1 clinical trials obtain FDA approval, which is why we followed a detailed roadmap for budgeting and advancing our new therapy at each stage of development.

The Model Of A Well-Funded Biotech Startup

Here are some business management changes to secure the future of biotech startups in 2023 and beyond.